The Cost of Prostate Biopsies and their Complications: A Summary of Data on All Medicare Fee-for-Service Patients over 2 Years. Issue 2 (29th March 2020)

• Record Type: Journal Article
• Authors: Weiner, Adam B.; Manjunath, Adarsh; Kirsh, Gary M.; Scott, Jeffrey A.; Concepcion, Raoul D.; Verniero, John; Kapoor, Deepak A.; Shore, Neal D.; Schaeffer, Edward M.
• Is Part Of: Urology practice. Volume 7:Issue 2(2020)
• Page Start: 145
• Page End: 151
• Publication Date: 2020-03-29
• Subjects: prostatic neoplasms -- epidemiology -- Medicare -- biopsy -- costs and cost analysis
• DOI: 10.1097/UPJ.0000000000000072
• Languages: English
• ISSNs: 2352-0779

Abstract

Abstract: Introduction: We define the cost of a contemporary prostate biopsy and the rate and incremental impact of complications on costs. Methods: A retrospective analysis of all Medicare fee-for-service claims for prostate biopsies in the United States from January 31, 2014 to December 1, 2015 was performed. Costs of each biopsy episode (including 30 days after each biopsy) were calculated. The effects of complications, biopsy setting and subsequent inpatient hospitalization were explored. Results: The average cost of the 234, 819 biopsies reviewed was $2, 020 and 46% of biopsy costs occurred in the 30 days following each biopsy. Biopsies performed in the office setting comprised 66% of the total and were least costly ($1, 750) compared to biopsies performed in ambulatory surgical centers ($2, 260) and outpatient hospital settings ($2, 730, both p <0.001). Biopsies performed in the office setting were associated with fewer complications (10%) compared to the outpatient hospital (19%) or ambulatory surgical center settings (12%, both p <0.001). An uncomplicated biopsy episode cost an average of $1, 740, which increased to $4, 060 when at least 1 complication occurred (difference +$2, 320, p <0.001). The largest charges incurred were related to inpatient admissions, which added $13, 840 to the cost of a prostate biopsy (p <0.001) but were rare, constituting only 2.8% of biopsies. Conclusions: Nearly half of costs during prostate biopsy episodes occur due to complications that occur in the days following a biopsy. These data should be used as benchmarks to incentivize interventions to reduce complications and subsequent admissions following biopsies.